glp-1 obesity news Antagonists Increase Plan Drug Spend - What's Next GLP-1 Use Has More Than
Description
Appetite and craving support
With the participation of researchers from the Paul Langerhans Institute Dresden (PLID), partner at the German Center for Diabetes Research, a GLP-1 receptor agonist in the form of tablets could for the first time be compared with the most common second-line therapy of T2D, a DPP-IV inhibitor
Anyway, we are currently facing a novel and very appealing therapeutic option.
- , ...
Within months of GLP-1 prescriptions written for obesity and overweight, JP Morgan analysts wrote an influential report on the drug category and implications for the health care industryand other sectors, notably food and beverage consumption
